The Role of Clinical and Instrumented Outcome Measures in Balance Control of Individuals with Multiple Sclerosis

Yamamoto, D., & Campbell, J. D. (2012). Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature. Autoimmune Diseases, 2012(), 375-387. https://doi.org/10.1155/2012/784364
Lavery, A. M., Verhey, L. H., & Waldman, A. T. (2014). Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials. Multiple Sclerosis International, (2014), 43-55. https://doi.org/10.1155/2014/262350
Bermel, R., Waldman, A., & Mowry, E. M. (2014). Outcome Measures in Multiple Sclerosis. Multiple Sclerosis International, (2014), 92-93. https://doi.org/10.1155/2014/439375
Prosperini, L., & Pozzilli, C. (2013). The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review. Multiple Sclerosis International, 2013(), 232-240. https://doi.org/10.1155/2013/756564
Healy, B. C., Engler, D., Glanz, B., Musallam, A., & Chitnis, T. (2013). Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis. Multiple Sclerosis International, 2013(), 36-44. https://doi.org/10.1155/2013/189624